Cagent Vascular Secures $15M Growth Capital from Trinity Capital

In a significant move within the medical technology industry, Trinity Capital Inc., a noted alternative asset manager, has committed $15 million in growth capital to Cagent Vascular Inc. The investment aims to enhance the latter's serration technology, which pioneers advancements in vessel dilation for endovascular interventions. Cagent Vascular's flagship product, the Serranator, aims to improve angioplasty procedures, benefiting patients suffering from peripheral artery disease by providing more predictable and less invasive treatment options. The financing from Trinity Capital, which complements the $45 million of equity financing led by US Venture Partners in 2024, is expected to boost Cagent Vascular's commercial infrastructure and promote broader clinical adoption of its technology. This partnership signifies Trinity Capital's strategic approach to investing in growth-oriented companies, particularly in the life sciences space, supporting the development of innovative solutions in health and medical technologies. Both firms anticipate that this infusion of capital will proliferate the advancement of medical technologies, ultimately improving patient outcomes on a global scale.